224 related articles for article (PubMed ID: 27034474)
1. Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus-Brief Report.
Apro J; Tietge UJ; Dikkers A; Parini P; Angelin B; Rudling M
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):787-91. PubMed ID: 27034474
[TBL] [Abstract][Full Text] [Related]
2. Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities.
Denimal D; Benanaya S; Monier S; Simoneau I; Pais de Barros JP; Le Goff W; Bouillet B; Vergès B; Duvillard L
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3816-e3823. PubMed ID: 35647758
[TBL] [Abstract][Full Text] [Related]
3. Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus.
Dullaart RPF; Pagano S; Perton FG; Vuilleumier N
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30744100
[TBL] [Abstract][Full Text] [Related]
4. The negative effect of ANGPTL8 on HDL-mediated cholesterol efflux capacity.
Luo M; Zhang Z; Peng Y; Wang S; Peng D
Cardiovasc Diabetol; 2018 Nov; 17(1):142. PubMed ID: 30409151
[TBL] [Abstract][Full Text] [Related]
5. The macrophage and its related cholesterol efflux as a HDL function index in atherosclerosis.
Yamamoto S; Narita I; Kotani K
Clin Chim Acta; 2016 Jun; 457():117-22. PubMed ID: 27087419
[TBL] [Abstract][Full Text] [Related]
6. Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes.
Murakami H; Tanabe J; Tamasawa N; Matsumura K; Yamashita M; Matsuki K; Murakami H; Matsui J; Suda T
Diabetes Res Clin Pract; 2013 Jan; 99(1):30-8. PubMed ID: 23137417
[TBL] [Abstract][Full Text] [Related]
7. Pre-β1 HDL in type 2 diabetes mellitus.
Shiu SW; Wong Y; Tan KC
Atherosclerosis; 2017 Aug; 263():24-28. PubMed ID: 28595104
[TBL] [Abstract][Full Text] [Related]
8. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes.
Patel S; Drew BG; Nakhla S; Duffy SJ; Murphy AJ; Barter PJ; Rye KA; Chin-Dusting J; Hoang A; Sviridov D; Celermajer DS; Kingwell BA
J Am Coll Cardiol; 2009 Mar; 53(11):962-71. PubMed ID: 19281927
[TBL] [Abstract][Full Text] [Related]
9. Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus.
Tan HC; Tai ES; Sviridov D; Nestel PJ; Ng C; Chan E; Teo Y; Wai DC
J Clin Lipidol; 2011; 5(6):467-73. PubMed ID: 22108150
[TBL] [Abstract][Full Text] [Related]
10. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
[TBL] [Abstract][Full Text] [Related]
11. HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.
Bhatt A; Rohatgi A
Curr Atheroscler Rep; 2016 Jan; 18(1):2. PubMed ID: 26710794
[TBL] [Abstract][Full Text] [Related]
12. Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration.
Monette JS; Hutchins PM; Ronsein GE; Wimberger J; Irwin AD; Tang C; Sara JD; Shao B; Vaisar T; Lerman A; Heinecke JW
Circ Res; 2016 Jun; 119(1):83-90. PubMed ID: 27114438
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
[TBL] [Abstract][Full Text] [Related]
14. Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients.
Apro J; Parini P; Broijersén A; Angelin B; Rudling M
J Lipid Res; 2015 Aug; 56(8):1633-9. PubMed ID: 26092865
[TBL] [Abstract][Full Text] [Related]
15. Lipid modification in type 2 diabetes: the role of LDL and HDL.
Vergès B
Fundam Clin Pharmacol; 2009 Dec; 23(6):681-5. PubMed ID: 19650852
[TBL] [Abstract][Full Text] [Related]
16. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.
Zhao D; Yang LY; Wang XH; Yuan SS; Yu CG; Wang ZW; Lang JN; Feng YM
Cardiovasc Diabetol; 2016 Sep; 15(1):132. PubMed ID: 27620179
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
18. Genetic determination of plasma cholesterol efflux capacity is gender-specific and independent of HDL-cholesterol levels.
Villard EF; EI Khoury P; Frisdal E; Bruckert E; Clement K; Bonnefont-Rousselot D; Bittar R; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):822-8. PubMed ID: 23372063
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein.
Hoang A; Drew BG; Low H; Remaley AT; Nestel P; Kingwell BA; Sviridov D
Eur Heart J; 2012 Mar; 33(5):657-65. PubMed ID: 21498847
[TBL] [Abstract][Full Text] [Related]
20. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy.
Zhou H; Tan KC; Shiu SW; Wong Y
Nephrol Dial Transplant; 2008 Mar; 23(3):927-33. PubMed ID: 18065800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
